Introduction
assumed, was to find the right dose of cells needed to completely repair the infarct and show functional Much of the morbidity and mortality from myocardial infarction results from the heart's inability improvement. Disillusionment soon followed, however, when quantitative, dose-response studies were to regenerate significant muscle mass in the infarct. Multiple groups, including our own, have studied undertaken. We observed no increase in graft size over an input range of 3 to 25 million cardiothe possibility of regenerating new muscle in infarcts by cellular implantation (cellular cardiomyocytes [9] . (For reference, the adult rat left ventricle contains >20 million cardiomyocytes [10].) myoplasty). It seems intuitive that the most natural approach would be to replace dead cardiomyocytes Furthermore, grafts were all small, never exceeding 2% of the left ventricle at one week after imwith new, living cardiomyocytes. Indeed, initial studies with cardiomyocyte transplantation genplantation. This suggested that graft cell death was limiting the amount of new myocardium formed. erated considerable excitement. Field's group, for example, showed that fetal cardiomyocytes formed Studies using TUNEL analysis showed that, although graft cells appeared viable shortly after stable grafts when implanted into the normal myocardium of mice and dogs, and that the graft implantation, by 24 hours >32% had fragmented DNA. Cell death continued for at least 4 days after cells formed intercalated disks with host myocytes [1] [2] [3] . Other groups, including our own, subimplantation, when the TUNEL index was 10%. By 1 week, the TUNEL index was >1%, suggesting sequently showed that fetal or neonatal cardiomyocytes could form stable grafts in infarcted the wave of cell death was largely complete.
In the current issue of The Journal, Mü lleror cryoinjured hearts [4] [5] [6] [7] [8] , although the grafts typically were located at the lesion's periphery, close
Ehmsen and co-workers have extended these observations using a clever and highly quantitative to host myocardium. molecular technique to measure graft cell number in the heart [11]. The authors implanted neonatal cardiomyocytes from male donors into normal hearts of syngeneic female rats. To quantify graft osteopontin (2 copies per diploid genome), was situ hybridization, coupled with cell type-specific antibody staining, to determine the relative number determined at various time points after injection of the cells for up to 12 weeks. This PCR-based apof graft cardiomyocytes and non-myocytes remaining at the end of the study. proach was highly sensitive, detecting 2 male cells amongst 50 000 female cells. It also yielded a 0. 993 It is noteworthy that the survival reported by Muller-Ehmsen et al. likely reflects a best-case correlation coefficient when compared with a known set of male:female DNA solutions, suggesting scenario, since the cardiomyocytes were grafted into normal hearts representing the least hostile a high degree of accuracy.
Several important pieces of new information environment. Indeed, our group found that death of grafted neonatal cardiomyocytes after 24 hours came from this study. The first was that graft cell seeding efficiency at 0-1 hour after injection is lowest in normal hearts, intermediate in vascularized 2 week-old injuries, and highest in acutely averaged only 58%. Even more impressive was the variability of seeding, which ranged from 10-90%.
injured hearts [9] . Grafting into an established injury probably resembles an eventual clinical situThis early variability cannot be due to death, since even cells killed by freeze-thaw showed a positive Y ation more closely, where cardiomyocytes likely would be transplanted some time after the infarct. chromosome signal at 1 hour. The authors reasoned that such rapid loss was caused by a combination Mü ller-Ehmsen et al. also showed the initial number of cells grafted in the heart could be increased of cell retention in the syringe's dead-space (presumably correctable by using a Hamilton syringe), by simply increasing the concentration of the cell suspension. On the other hand, increasing the numleakage from the injection site, and wash-out through the vasculature. Indeed, our own exber of cells seeded had no effect on the final number surviving. This result agrees well with our previous perience with cell grafting indicates that these factors certainly play a role, resulting in a highly dose-response study and suggests that the cells are competing for limited resources for survival. In their variable graft size [12] . Given the variability occurs in laboratories with extensive experience with cell study, the survival curve plateaued at >1 million cells, indicating perhaps an optimal number of cells injection in the heart, it seems unlikely that more practice is needed to improve the results. Rather, to implant in the normal heart. Why do so many cardiomyocytes die after graftthe basic protocol for cell grafting may need further optimization to prevent cell loss. On a ing? Mü ller-Ehmsen found no benefit to survival when the cardiomyocytes were treated with the positive note, some of the technical obstacles may be caused by the use of small animals with high broad spectrum caspase inhibitor AcYVADcmk prior to grafting. They interpreted this to mean that heart rates and would likely disappear in human patients.
caspase-independent mechanisms are responsible for most of the death. It is important to note, Next, Muller-Ehmsen et al. showed that over the first 24 hours there was a considerable loss of graft however, that the inhibitor used is a ''suicide substrate'' for caspases, which will inhibit the enzymes cells, down to 24% of the injected cell number (41% of the initial seeding number). Over the ensuing only when they are active. If the caspases were in their pro-form in vitro and activated after cell weeks the number of graft cells remained relatively constant, with just a borderline further reduction implantation, in vitro pre-treatment would not be expected to have an effect. As mentioned above, our to 15% of those injected (26% of initial seeding number) at 12 weeks. Although these data indicate own studies showed markedly improved survival when cells were grafted into vascularized tissues, that substantial cell death occurred after grafting, the authors are careful to emphasize that this techsuggesting ischemia was a major source of injury [9] . We observed modestly protective effects by nique likely underestimated cardiomyocyte death. Like all cardiomyocyte isolations, theirs contained transfecting the cells with a constitutively active form of the cytoprotective protein kinase, Akt, ina fraction of non-myocytes, which they estimated at 20% prior to implantation. The Y chromosome dicating there might be a role for apoptosis in inducing cell death. We saw dramatic protection PCR assay, of course, cannot distinguish between myocytes and non-myocytes. It is likely that the when the graft cells were heat shocked one day prior to implantation. Although providing a pracmyocytes were preferentially killed after implantation, whereas the fibroblasts likely protical means to enhance survival, heat shock is not a precise molecular intervention and, unfortunately, liferated. Thus, cardiomyocyte survival after grafting was likely to be substantially lower than sheds little light on the mechanism of death. It is interesting to speculate on a possible role for nonthe 15% value reported at the end of the study. It would be useful to utilize a Y chromosome in myocytes in myocyte death. Standard protocols for cardiomyocyte isolation are designed to minimize
